Biogen recently announced that its new standalone, publicly traded worldwide biotechnology company dedicated to hemophilia is named Bioverativ and will launch early next year.
The goal of Bioverativ is to speed the innovations that will help people who have hemophilia as well as other blood disorders. The company will focus on finding, researching, creating and selling treatments for these health conditions.
“As an independent and focused company, we believe that Bioverativ will be uniquely positioned to drive progress and advance the standard of care for people living with hemophilia,” John Cox, CEO of Bioverativ and former Biogen executive vice president, said. “Working closely with the hemophilia community, we hope to transform lives by accelerating innovation for people and caregivers living with hemophilia.”
In addition, Bioverativ will market Eloctate and Alprolix to treat hemophilia A and B. This will be done through Biogen’s current partnership with Swedish Orphan Biovitrum AB. Bioverativ will also continue its ongoing development of these products while studying the benefits of the treatment.
“The new company’s name creates a clear connection to our Biogen heritage and biotech focus,” Cox said. “It also conveys our commitment to actively working with patients, caregivers, health care professionals and advocacy leaders to create progress where patients need it most.”
